Passage Bio Stock Analysis

Passage Stock Analysis Notes

About 52.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.91. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Passage Bio recorded a loss per share of 14.62. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 14th of July 2025. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To find out more about Passage Bio contact William MD at 267 866 0311 or learn more at https://www.passagebio.com.

Passage Bio Investment Alerts

Passage Largest EPS Surprises

View All Earnings Estimates

Passage Bio Environmental, Social, and Governance (ESG) Scores

Passage Stock Institutional Investors

Note, although Passage Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Passage Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.63 M.

Passage Profitablity

Management Efficiency

Passage Bio has return on total asset (ROA) of (0.3166) % which means that it has lost $0.3166 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8718) %, meaning that it created substantial loss on money invested by shareholders. Passage Bio's management efficiency ratios could be used to measure how well Passage Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.76. The current Return On Capital Employed is estimated to decrease to -1.02. At this time, Passage Bio's Total Assets are most likely to increase significantly in the upcoming years. The Passage Bio's current Total Current Assets is estimated to increase to about 141.2 M, while Net Tangible Assets are projected to decrease to roughly 166.4 M.

Technical Drivers

As of the 11th of February 2026, Passage Bio holds the Semi Deviation of 6.63, coefficient of variation of 1014.28, and Risk Adjusted Performance of 0.088. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Passage Bio, as well as the relationship between them. Please check Passage Bio information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Passage Bio is priced some-what accurately, providing market reflects its current price of 9.32 per share. Given that Passage Bio has jensen alpha of 0.434, we recommend you to check out Passage Bio's recent market performance to make sure the company can sustain itself at a future point.

Passage Bio Price Movement Analysis

Passage Bio Insider Trading Activities

Passage Bio Outstanding Bonds

Passage Bio Predictive Daily Indicators

Passage Bio Corporate Filings

Passage Bio Forecast Models

Passage Bio's time-series forecasting models are one of many Passage Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Passage Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Passage Bio Bond Ratings

Passage Bio financial ratings play a critical role in determining how much Passage Bio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Passage Bio's borrowing costs.

Passage Bio Debt to Cash Allocation

Passage Bio currently holds 25.48 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Passage Bio has a current ratio of 9.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Passage Bio's use of debt, we should always consider it together with its cash and equity.

Passage Bio Total Assets Over Time

Passage Bio Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Passage Bio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Passage Bio Debt Ratio

14.0

It seems as most of the Passage Bio's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Passage Bio's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Passage Bio, which in turn will lower the firm's financial flexibility.

Passage Bio Corporate Bonds Issued

Passage Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Passage Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Passage shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Passage Bio. By using and applying Passage Stock analysis, traders can create a robust methodology for identifying Passage entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Passage analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Passage analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Passage Bio stock analysis indicators help investors evaluate how Passage Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Passage Bio shares will generate the highest return on investment. By understating and applying Passage Bio stock analysis, traders can identify Passage Bio position entry and exit signals to maximize returns.

When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.